#SABCSSnippets: Marcela Mazo talked with Marjolein Smidt at #SABCS25 about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.
buff.ly/MrXAKvF
#SABCSSnippets: Saba Shaikh talked with Sonia Pernas at #SABCS25 about the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib + fulvestrant showed efficacy in HR+ metastatic breast cancer patients previously treated with a CDK4/6 inhibitor. buff.ly/gkjdRPf
#SABCSSnippets: Rahul Gosain of the Oncology Brothers talked with Marleen Kok at #SABCS25 about how lobular carcinoma—which comprises 10-15% of all invasive breast cancers—differs from ductal carcinoma.
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social
#SABCSSnippets at #SABCS25: Julie Nangia and @ErikaHamilton9 discussed HER2CLIMB-05, which showed that adding tucatinib to 1st-line maintenance therapy with trastuzumab and pertuzumab delayed progression in patients with HER2+ metastatic breast cancer.
buff.ly/YIwYQEh @erikahamilton9.bsky.social
WISDOM's founder Dr. Laura Esserman sat down with San Antonio Breast Cancer Symposium Co-director Virginia Kaklamani, MD to discuss the results of WISDOM 1.0.
Watch full interview on Youtube. Link in bio!
San Antonio Breast Cancer Symposium
#SABCSSnippets
#SABCSSnippets: Virginia Kaklamani talked with Hope Rugo at #SABCS25 about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study.
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social
#SABCSSnippets: Virginia Kaklamani talked with Laura Esserman about the results of the WISDOM 1.0 study, which demonstrated that risk-based breast cancer screening is safe, preferred by women, and identifies the highest risk individuals.
buff.ly/DFByGvB @vkaklamani.bsky.social
